Table 2 Univariate and multivariate analysis of FRGS, clinical and pathologic factors with DFS of stage II/III patients in training and validation cohorts
Characteristic | Training cohort (GSE39582, n = 461) | Validation-1 cohort (TCGA, n = 338) | Validation-2 cohort (meta-validation, n = 553) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Univariate | Multivariate | Univariate | Multivariate | Univariate | Multivariate | |||||||
HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | |
FRGS | 3.33 (1.95–5.68) | < 0.001 | 3.19 (1.88–5.41) | < 0.001 | 5.00 (1.58–15.85) | < 0.01 | 5.00 (1.58–15.85) | < 0.01 | 3.25 (1.55–6.81) | < 0.01 | 2.99 (1.44–6.21) | < 0.01 |
Gender | 1.53 (0.89–2.62) | 0.12 |  |  | 1.56 (0.81–2.99) | 0.18 |  |  | 0.70 (0.42–1.16) | 0.16 |  |  |
Age | 1.01 (0.99–1.03) | 0.58 |  |  | 1.01 (0.98–1.04) | 0.37 |  |  | 0.98 (0.97–1.00) | 0.07 |  |  |
Tumor location | 1.08 (0.64–1.84) | 0.78 |  |  | 1.09 (0.59–2.04) | 0.78 |  |  | 0.82 (0.40–1.66) | 0.58 |  |  |
TNM stage | 7.89 (1.11–55.91) | 0.01 | 7.46 (1.05–52.99) | 0.04 | 1.83 (0.76–4.41) | 0.17 |  |  | 3.59 (1.30–9.93) | < 0.01 | 3.39 (1.22–9.40) | 0.02 |
MMR status | 1.63 (0.70–3.82) | 0.25 |  |  | 0.64 (0.34–1.24) | 0.18 |  |  | 0.88 (0.38–2.04) | 0.76 |  |  |
CIMP status | 0.95 (0.44–2.02) | 0.89 |  |  |  |  |  |  | 0.91 (0.36–2.28) | 0.84 |  |  |
CIN status | 1.69 (0.75–3.81) | 0.2 |  |  |  |  |  |  |  |  |  |  |
TP53 mutation | 1.39 (0.78–2.48) | 0.27 |  |  |  |  |  |  | 2.74 (0.60–12.43) | 0.17 |  |  |
KRAS mutation | 1.44 (0.86–2.40) | 0.16 |  |  | 1.02 (0.23–4.60) | 0.98 |  |  | 1.23 (0.53–2.87) | 0.63 |  |  |
BRAF mutation | 1.42 (0.57–3.58) | 0.45 |  |  | 0.00 (0.00–Inf) | 0.72 |  |  | 2.04 (0.81–5.10) | 0.12 |  |  |